Skip to content
  • 99%+ HPLC PURITY
  • MASS-SPEC CONFIRMED IDENTITY
  • ISO/IEC 17025 LABS
  • COA PUBLISHED PER LOT
  • ENDOTOXIN SCREENED
  • HEAVY METALS PANEL
  • COLD-CHAIN HANDLED
  • US SYNTHESIS & FULFILLMENT
  • SAME-DAY DISPATCH
  • LOT-TRACEABLE TO LABEL
LUMENPEPTIDESLUMEN PEPTIDES
LUMENPEPTIDESBPC-15710 MG99.4% PURITY · HPLCRESEARCH USE ONLY · NOT FOR HUMAN USELOT LP-2601-A
99.4% purityRegenerative & RepairUSA made

BPC-157

Pentadecapeptide fragment of body protection compound. The most requested reference material in our catalog.

Price per vial

$62/ 10mg

99.4%HPLC
1
  • Third-party HPLC + LC-MS
  • COA published per lot
  • Insulated cold-chain dispatch
  • Free shipping over $250
View this lot’s certificate
40+
Published studies
15
Amino acid sequence
GHR upregulation
4
Research areas

Figures are illustrative of published preclinical research and are provided for orientation only. They are not claims about this product.

— About this compound

What BPC-157 is

BPC-157 is a synthetic pentadecapeptide — a chain of fifteen amino acids corresponding to a partial sequence of Body Protection Compound, a protein identified in gastric juice. It is supplied lyophilised as a stable reference standard and is one of the most widely requested peptides in preclinical tissue-repair literature.

Class
Synthetic pentadecapeptide
Residues
15 amino acids
Origin
Partial sequence of BPC
Form
Lyophilised powder
Sequence
  1. G
  2. E
  3. P
  4. P
  5. P
  6. G
  7. K
  8. P
  9. A
  10. D
  11. D
  12. A
  13. G
  14. L
  15. V
BACKBONE IMPRESSION · NOT A STRUCTURAL MODEL
— Mechanism

How BPC-157
has been studied.

Signalling pathways examined in preclinical models. Descriptive of published research directions, not claims of effect.

VEGF axis

Angiogenic signalling

Preclinical work has examined BPC-157 in the context of vascular endothelial growth factor signalling and the formation of new microvasculature in injured tissue models.

  • Studied in relation to VEGF receptor expression
  • Examined in endothelial migration assays
  • Investigated in vascular occlusion models
GH axis

Growth hormone receptor expression

A body of in-vitro work has looked at BPC-157 alongside growth hormone receptor expression in fibroblast and tendon-derived cell cultures.

  • Assessed in tendon fibroblast cultures
  • Examined against receptor expression markers
  • Studied in collagen-producing cell lines
Tissue integrity

Cytoprotective response

Much of the original literature characterised the parent compound in gastrointestinal mucosal models, where cytoprotective behaviour was the primary observation.

  • Characterised in gastric mucosal models
  • Examined under NSAID-challenge conditions
  • Studied in relation to epithelial barrier markers
— Uses & applications

What BPC-157 is researched for

Musculoskeletal

Tendon and ligament models

Frequently used in preclinical models examining connective tissue repair, collagen organisation, and fibroblast behaviour.

Gastrointestinal

Mucosal integrity

The compound's original characterisation was in gastric and intestinal models, which remains an active area of published work.

Neurological

Peripheral nerve models

Investigated in peripheral nerve injury preparations and in relation to neurotrophic signalling markers.

Vascular

Endothelial studies

Examined in vessel-formation and endothelial-migration assays alongside angiogenic markers.

Study-reported magnitudes

Representative figures

Tendon healing rate
72%
GHR expression increase
700%
Gastric lesion reduction
85%
Collagen fibre organisation
68%

Illustrative of published preclinical findings. Not a representation of this product’s performance, and not a claim of any effect in humans.

— Third-party verified

Independently tested.
Verifiably pure.

  • HPLC purity

    RP-HPLC, 214 nm

    PASS
  • Identity

    LC-MS

    CONFIRMED
  • Endotoxin (LAL)

    Kinetic chromogenic

    PASS
  • Heavy metals

    ICP-MS

    PASS
  • Net peptide content

    Nitrogen analysis

    VERIFIED
  • Residual solvents

    Headspace GC

    PASS
Certificate of analysis

Lot LP-2601-A

PASS
RP-HPLC · 214nm2026-01-14
HPLC purity
99.4%
Identity
Confirmed by LC-MS
Endotoxin (LAL)
< 0.5 EU/mg
Heavy metals
Pass
View full certificate
— Full specification

Every field on the label

Sequence
GEPPPGKPADDAGLV
Molecular formula
C62H98N16O22
Molecular weight
1419.53 g/mol
CAS / identifier
137525-51-0
Quantity per vial
10 mg
Purity
99.4% by RP-HPLC, 214 nm
Identity
Confirmed by LC-MS
Appearance
White to off-white lyophilised cake
Solubility
Soluble in bacteriostatic water and 0.9% NaCl
Storage
-20°C long term, 2-8°C in use
Endotoxin
< 0.5 EU/mg
Heavy metals
Below limit of quantitation
Country of origin
United States
Lot
LP-2601-A
Assay date
2026-01-14
— Common questions

About BPC-157

Still unsure? Ask the lab — median response under four hours.

A synthetic fifteen–amino-acid peptide corresponding to a partial sequence of Body Protection Compound, a protein originally isolated from gastric juice. We supply it lyophilised as an analytical reference standard.

No. BPC-157 is not an approved drug and has not been evaluated by the FDA for any use. It is sold here strictly as a research reference material and is not intended for human or veterinary consumption.

Each lot is assayed by reverse-phase HPLC at 214 nm for purity and by LC-MS for identity confirmation, at an accredited third-party laboratory. Endotoxin and heavy metals panels run in parallel. The full chromatogram is published with the lot, not just the headline figure.

Store the sealed vial at −20°C for long-term stability and 2–8°C for short-term handling. Protect from light and avoid repeated freeze-thaw cycles. Compound-specific stability data is printed on the certificate of analysis supplied with the lot.

This material is supplied as a reference standard for in-vitro laboratory research only. It has not been evaluated by the FDA, is not a drug, and is not intended for human or veterinary use. Handling should follow your institution's chemical hygiene plan, including appropriate PPE and documented disposal.

— Cited sources

Published literature

Independent published research relating to this compound. Listed for reference; Lumen Peptides, Inc. is not affiliated with these authors and makes no claims based on their findings.

  1. [1]

    Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract

    Sikiric P et al. · 2011 · Current Pharmaceutical Design

  2. [2]

    The promoting effect of pentadecapeptide BPC 157 on tendon healing

    Chang CH et al. · 2014 · Journal of Applied Physiology

  3. [3]

    Stable gastric pentadecapeptide BPC 157 and vascular occlusion

    Sikiric P et al. · 2019 · Current Neuropharmacology

  4. [4]

    Brain-gut axis and pentadecapeptide BPC 157

    Sikiric P et al. · 2016 · Current Neuropharmacology

For laboratory research use only. All compounds listed on this site are sold strictly as reference materials for in-vitro laboratory research conducted by qualified professionals. They are not drugs, foods, cosmetics, or medical devices. They are not intended for human or veterinary consumption, therapeutic use, diagnostic application, or any in-vivo use whatsoever. These statements have not been evaluated by the Food and Drug Administration. By purchasing, you affirm that you are a qualified researcher and that you will comply with all applicable institutional, local, state and federal regulations governing the handling of research chemicals.

Analytics cookies

We’d like to measure how the catalog is used, which sets cookies and shares activity with Meta. Nothing loads until you choose, and declining does not affect your order. Privacy policy